Consecutive measurements show association of IGF-1 with fetal growth in type 1 diabetic pregnancy
Main Article Content
Abstract
Background: Abnormal fetal growth can lead to adverse outcomes in pregnancy as well in later postnatal life and is more prevalent in diabetic pregnancies. These are usually associated with large for gestational age neonates, an issue that has already been broadly examined. On the other side, diabetes in pregnancy can also relate to intrauterine growth restriction and small for gestational age neonates. During pregnancy, maternal IGF-1 is secreted excessively and additionally produced by placenta, which regulates transport of nutrients to the fetus acting through an IGF-receptor and accordingly affects its growth. As type 1 diabetes carries a higher risk of adverse events associated with fetal growth there is a natural focus on possible links between IGF-1 and fetal growth.
Aim: The present study investigated the time-course relationship between the maternal serum IGF-1 and the birthweight as an obstetrical outcome in type 1 diabetic pregnancies with various levels of background risk.
Methods: 130 pregnant women with type 1 diabetes were consecutively recruited for measurement of growth factors, genes affecting coagulation, evaluated for diabetes status, and perinatal outcome. The birthweight z-score was computed and grouped into tertiles for analysis of association with repeated measurements of IGF-1. Diurnal blood pressure was measured by monitor. Retinopathy grade was evaluated by two specialists independently, blinded of the clinical data. Blood samples for IGF-1 during pregnancy were drawn from week 6 and every 4th week until week 30, then every 2 nd week. Genomic DNA was extracted from peripheral blood.
Results: The median of the lowest tertile of birthweight z-score was 0.4 (-1 - +1.3) and included more women with micro/macroalbuminuria than the middle and upper tertile; however, ¾ had normoalbuminuria and no further sign of surplus vasculopathy compared to the other tertile groups. The lowest birthweights were associated with a lower rise in IGF-1 from week 22 to 32. Neither glycemic control, genetics, grade of retinopathy, renal function nor vascular resistance indices in diurnal blood pressure were different between the tertile groups.
Conclusion: Our main finding is that lower IGF-1 levels are associated with subsequent lower birthweight in diabetic pregnancy and is displayed markedly at the end of 2nd trimester. We hypothesize that the relative low birthweight, despite being within the limits of appropriate for gestational age may display inappropriate growth if not outright growth-restriction. We were able to discern different levels of growth at a critical point in pregnancy where ultrasound may pick up different levels of growth patterns and optimized care can be commenced.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Tong S, Kaitu'u-Lino TJ, Walker SP, MacDonald TM. Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. Prenatal Diagnosis. 2019 Oct;39(11):947-957. doi: 10.1002/pd.5525.
3. Kajdy A, Modzelewski J, Jakubiak M, Pokropek A, Rabijewski M. Effect of antenatal detection of small-for-gestational-age newborns in a risk stratified retrospective cohort. PLoS One. 2019; 14(10): e0224553. doi: 10.1371/journal.pone.0224553
4. Renes JS, van Doorn J, Hokken-Koelega ACS. Current Insights into the Role of the Growth Hormone-Insulin-Like Growth Factor System in Short Children Born Small for Gestational Age. Horm Res Paediatr. 2019 Dec; 92(1): 15–27. doi: 10.1159/000502739.
5. DiPrisco B, Kumar A, Kalra B et al. Placental proteases PAPP-A and PAPP-A2, the binding proteins they cleave (IGFBP-4 and -5), and IGF-1 and IGF-1I: Levels in umbilical cord blood and associations with birthweight and length. Metabolism. 2019 Nov;100:153959. doi: 10.1016/j.metabol.2019.153959.
6. Lauszus FF, Klebe JG, Flyvbjerg A. Macrosomia associated with maternal serum insulin-like growth factor-I and -II in diabetic pregnancy. Obstet Gynecol. 2001 May;97(5 Pt 1):734-41. doi: 10.1016/s0029-7844(01)01189-9.
7. Fuglsang J, Lauszus FF, Flyvbjerg A, Ovesen P. Human placental growth hormone, insulin-like growth factor I and -II, and insulin requirements during pregnancy in type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 4355-61. doi: 10.1210/jc.2003-030726.
8. Gibson JM, Westwood M, Lauszus FF, Klebe JG, Flyvbjerg A, White A. Phosphorylated insulin-like growth factor binding protein-1 is increased in pregnant diabetic subjects. Diabetes 1999; 48: 321-326 doi: 10.2337/diabetes.48.2.321
9. Vandenberghe G, Mensink I, Twisk JWR, Blankenstein MA, Heijboer AC, van Vugt JMG. First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia. Prenat Diagn. 2011 Oct;31(10):955-61. doi: 10.1002/pd.2807
10. Hellström A, Ley D, Hansen‐Pupp I, Hallberg B et al. Insulin‐like growth factor 1 has multisystem effects on foetal and preterm infant development. Acta Paediatr. 2016 Jun; 105(6): 576–586. doi: 10.1111/apa.13350
11. Hellström A, Ley D, Hansen-Pupp I et al. Role of Insulin-like Growth Factor 1 in Fetal Development and in the Early Postnatal Life of Premature Infants. Am J Perinatol. 2016 Sep;33(11):1067-71. doi: 10.1055/s-0036-1586109.
12. Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH, Stehouwer CDA, Eurodiab ProspectivE Complications Study Group. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study.
J Intern Med 2005;258(5):450-9. doi: 10.1111/j.1365-2796.2005.01560.x
13. Xiaoming W, Kunxian Y, Xiaodan T et al. Folate metabolism gene polymorphisms MTHFR C677T and A1298C and risk for preeclampsia: a meta-analysis. J Assist Reprod Genet 201532(5):797-805. doi: 10.1007/s10815-014-0408-8
14. Hill DJ, Flyvbjerg A, Arany E, Lauszus FF, Klebe JG. Increased levels of serum fibroblast growth factor-2 (FGF-2) in diabetic pregnant women with retinopathy. J Clin Endocrinol Metab 1997; 82: 1452-57. doi: 10.1210/jcem.82.5.3915
15. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996; 85(7):843–848. doi:10.1111/j.1651-2227.1996.tb14164.x
16. Dolan E, Li Y, Thijs L et al. Ambulatory arterial stiffness index: rationale and methodology. Blood Pressure Monit. 11 (2006) 103–105, doi:10.1097/01.mbp.0000200478.19046.dd
17. Frystyk J, Dinesen B, Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human IGF-1 and -II. Growth Regul 1995;5:169 –76. PMID: 8745141
18. Jinks DC, Minter M, Tarver DA et al. Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet 1989; 81: 363-366. doi:10.1007/BF00283692.
19. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113, doi:10.1038/ng0595-111.
20. Gaustadnes M, Rüdiger N, Möller J et al. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis 1999; 10: 251-9. doi: 10.1097/00001721-199907000-00006.
21. Teramo K, Kari MA, Eronen M, Markkanen H, Hiilesmaa V. High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies. Diabetologia. 2004 Oct;47(10):1695-703. doi: 10.1007/s00125-004-1515-3.
22. Hill WC, Pelle-Day G, Kitzmiller JL, Spencer EM. IGFs in fetal macrosomia with and without maternal diabetes. Horm Res 1989; 32:178–82. doi: 10.1159/000181285.
23. Holmes RP, Holly JM, Soothill PW. A prospective study of maternal serum insulin-like growth factor I in pregnancies with appropriately grown or growth restricted fetuses. Br J Obstet Gynaecol 1998;105:1273– 8. doi: 10.1111/j.1471-0528.1998.tb10005.x.
24. Delmis J, Drazancic A, Ivanisevic M, Suchanek E. Glucose, insulin, hGH, and IGF-1 levels in maternal serum, amniotic fluid and umbilical serum: A comparison between late normal pregnancy and pregnancies complicated with diabetes and fetal growth retardation. J Perinat Med 1992;20:47–56. doi: 10.1515/jpme.1992.20.1.47.
25. Caufriez A, Frankenne F, Hennen G, Copinschi G. Regulation of maternal IGF-1 by placental growth hormone in pregnancy. Possible action of maternal IGF-1 on fetal growth. Horm Res 1994;42: 62–5. doi: 10.1159/000184147.
26. Langford KS, Nicolaides KH, Jones J, Abbas A, McGregor AM, Miell JP. Serum IGFBP-3 levels and IGFBP-3 protease activity in normal, abnormal, and multiple pregnancy. J Clin Endocrinol Metab 1995;80:21–7. doi: 10.1210/jcem.80.1.7530257.
27. Higgins MF, Russell NE, Crossey PA, Nyhan KC, Brazil DP, McAuliffe FM. Maternal and Fetal Placental Growth Hormone and IGF Axis in Type 1 Diabetic Pregnancy. PloS One. 2012;7(2):e29164. doi: 10.1371/journal.pone.0029164.
28. Chiesa C, Osborn JF, Haass C et al. Ghrelin, leptin, IGF-1, IGFBP-3, and insulin concentrations at birth: is there a relationship with fetal growth and neonatal anthropometry? Clin Chem 2008;54(3):550-8. doi: 10.1373/clinchem.2007.095299.
29. Elhddad ASA, Lashen H. Fetal growth in relation to maternal and fetal IGF-axes: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2013;92(9):997-1006. doi: 10.1111/aogs.12192.
30. Malamitsi-Puchner A, Briana DD, Gourgiotis D et al. Insulin-like growth factor (IGF)-I and insulin in normal and growth-restricted mother/infant pairs. Mediators Inflamm 2007;2007:42646. doi: 10.1155/2007/42646.
31. Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH. Maternal serum insulin-like growth factor (IGF-1) and binding proteins IGFBP-1 and IGFBP-3 at 11-13 weeks’ gestation in pregnancies delivering small for gestational age neonates. Eur J Obstet Gynecol Reprod Biol. 2012;161(1):30-3. doi: 10.1016/j.ejogrb.2011.12.022.
32. Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care. 2009;32(1):38-44. doi: 10.2337/dc08-1526.
33. Bowman CJ, Streck RD, Chapin RE. Maternal-placental insulin-like growth factor (IGF) signaling and its importance to normal embryo-fetal development. Birth Defects Res B Dev Reprod Toxicol 2010;89(4):339-49. doi: 10.1002/bdrb.20249.
34. Skajaa GO, Kampmann U, Fuglsang J, Ovesen PG. High prepregnancy HbA1c is challenging to improve and affects insulin requirements, gestational length, and birthweight. J Diabetes. 2020;12(11):798-806. doi: 10.1111/1753-0407.13070.